ACANYA Drug Patent Profile

Which patents cover Acanya, and what generic alternatives are available?

Acanya is a drug marketed by Bausch and is included in one NDA. There are six patents protecting this drug.

The generic ingredient in ACANYA is benzoyl peroxide; clindamycin phosphate. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Acanya

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACANYA

US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
Drug Prices:	Drug price information for ACANYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACANYA
What excipients (inactive ingredients) are in ACANYA?	ACANYA excipients list
DailyMed Link:	ACANYA at DailyMed

See drug prices for ACANYA

See drug sales revenues for ACANYA

Recent Clinical Trials for ACANYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Taro Pharmaceuticals USA	Phase 1
Watson Laboratories, Inc.	Phase 3
Padagis LLC	Phase 3

See all ACANYA clinical trials

Pharmacology for ACANYA

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

US Patents and Regulatory Information for ACANYA

ACANYA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	8,288,434		Y
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	10,624,918
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	8,895,070

Expired US Patents for ACANYA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	5,733,886
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	6,117,843

International Patents for ACANYA

When does loss-of-exclusivity occur for ACANYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

European Patent Office

Japan

Mexico

Portugal

Russian Federation

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ACANYA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009255679
Brazil	PI0913326
Canada	2723029	FORMULATIONS PHARMACEUTIQUES TOPIQUES CONTENANT UNE FAIBLE CONCENTRATION DE PEROXYDE DE BENZOYLE EN SUSPENSION DANS DE L'EAU ET UN SOLVANT ORGANIQUE MISCIBLE AVEC L'EAU (TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT)

Supplementary Protection Certificates for ACANYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009

Acanya Market Dynamics and Financial Trajectory: FDA Status, Generic Competition, Patents, and Commercial Outlook

Last updated: September 23, 2026

Acanya is a prescription topical acne gel combining clindamycin phosphate 1.2% and benzoyl peroxide 2.5%. The product received FDA approval in 2008 and was commercialized by Medicis, later acquired by Valeant Pharmaceuticals, now Bausch Health. Its commercial opportunity depended on branded pricing and differentiated formulation rather than a novel active ingredient. Generic clindamycin phosphate/benzoyl peroxide products have materially reduced Acanya’s market value, and no current standalone revenue series is publicly disclosed.

The product has no biosimilar risk because it is a chemically synthesized, non-biologic topical drug. Its main competitive risks are generic substitution, lower-cost combination gels, alternative topical acne therapies, and reimbursement pressure.

What is Acanya and how does the product work?

Acanya is a fixed-dose topical combination for acne vulgaris. Each gram contains:

Attribute	Acanya
Active ingredients	Clindamycin phosphate and benzoyl peroxide
Strength	1.2% clindamycin phosphate and 2.5% benzoyl peroxide
Dosage form	Topical gel
Therapeutic area	Acne vulgaris
FDA pathway	New drug application
Pharmacologic classes	Topical lincosamide antibiotic and oxidizing antimicrobial
Primary commercial rationale	Combination treatment with reduced need for separate products

Clindamycin suppresses Cutibacterium acnes and reduces inflammatory activity. Benzoyl peroxide has antimicrobial and keratolytic effects. Its inclusion also addresses a central limitation of topical antibiotic therapy: the risk of bacterial resistance when antibiotics are used without benzoyl peroxide.

The formulation competed with other fixed-dose topical acne combinations, including Duac, which combines clindamycin and benzoyl peroxide at a different strength, and generic versions of clindamycin/benzoyl peroxide gels.

When was Acanya FDA-approved and who commercialized it?

The FDA approved Acanya in 2008 for the topical treatment of acne vulgaris. Medicis Pharmaceutical Corporation developed and commercialized the product. Valeant acquired Medicis in 2012 in a transaction valued at approximately $2.6 billion, bringing Acanya into Valeant’s dermatology portfolio.[1][2]

The ownership sequence was commercially important:

Period	Corporate owner or commercial sponsor	Strategic context
2008 onward	Medicis	Specialty dermatology launch
2012 onward	Valeant Pharmaceuticals	Acquired Medicis and its dermatology portfolio
2018 onward	Bausch Health Companies	Valeant rebranded as Bausch Health
Current commercial position	No separately disclosed Acanya revenue stream	Mature or discontinued branded-product economics

Acanya was part of a broader dermatology portfolio that included branded acne, rosacea, psoriasis, and aesthetic products. Public company filings generally reported dermatology or prescription-product revenue at an aggregated level. They did not provide a reliable, recurring Acanya-specific revenue line.

What were Acanya’s main market drivers?

Acanya’s market entry benefited from several commercial factors:

1. Combination therapy reduced the inconvenience of prescribing separate clindamycin and benzoyl peroxide products.
2. Dermatology practices often used branded topical products with higher per-unit prices than older generic ingredients.
3. The product addressed inflammatory acne, a large and recurring outpatient market.
4. The formulation was positioned as a convenient alternative to separately administered topical therapies.
5. Medicis had established relationships with dermatologists and specialty pharmacies.

The market was competitive from the outset. Acne treatment includes inexpensive generic benzoyl peroxide, topical retinoids, topical antibiotics, oral antibiotics, hormonal therapies, and newer branded agents such as topical retinoid and antimicrobial combinations. Patient adherence, tolerability, insurance coverage, and copay levels influence prescribing as much as clinical differentiation.

Acanya’s commercial differentiation weakened as physicians and payers gained access to lower-priced generic combinations. The active ingredients were familiar, and the product did not establish a durable barrier comparable to a novel molecular entity or a biologic platform.

How did Acanya’s financial trajectory develop?

Acanya’s financial trajectory followed the typical pattern for a branded topical combination product.

Launch and specialty-dermatology growth

During the early commercial period, Acanya could command a premium relative to its ingredient cost because of branded status, physician promotion, and the convenience of a fixed-dose product. Its financial contribution was likely strongest during the years before broad generic substitution.

The available public filings do not support a verified product-level revenue figure. Valeant and Bausch Health reported results by broader business segments, and Acanya was not consistently identified as a material standalone revenue contributor.[3][4]

Portfolio ownership and price pressure

After Valeant acquired Medicis, Acanya became part of a larger dermatology portfolio. Valeant’s business model relied heavily on branded and specialty products with price and volume expansion. The company faced increasing scrutiny over drug pricing, acquisition-driven growth, debt levels, and revenue quality. These factors affected the valuation of its dermatology portfolio even when products remained commercially active.

Acanya was less strategically defensible than products with a novel active ingredient, proprietary delivery system, or long-duration exclusivity. The product’s economic value therefore depended heavily on the timing of generic entry.

Generic erosion

Generic clindamycin phosphate and benzoyl peroxide gels reduced the addressable branded market. Once generic alternatives became available, payers and pharmacy benefit managers had strong incentives to favor them. Dermatologists could also prescribe the same active ingredients at lower cost.

For a topical acne product, generic erosion can be rapid because:

• The active ingredients are well established.
• The product is not biologic and does not require complex interchangeability analysis.
• Patients generally use small quantities and can switch products without administration training.
• Prescribers have multiple topical alternatives.
• Retail and specialty pharmacies can substitute based on formulary terms.

The likely commercial outcome was a decline in Acanya prescription volume, net price, or both. Public filings do not provide a defensible standalone estimate of the percentage decline.

What is the FDA regulatory status of Acanya?

Acanya was approved through an FDA new drug application rather than an abbreviated new drug application. FDA databases distinguish the original branded product from later generic approvals.

The key regulatory issues are:

Regulatory issue	Assessment
FDA approval	Yes, for topical acne treatment
Drug type	Small-molecule topical combination
Biologic license application	No
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated new drug application
Orange Book relevance	Applicable to the approved NDA and listed patents
Current commercial activity	No public standalone sales disclosure
Regulatory risk	Lower than for a biologic, but dependent on current listing and marketing status

A product’s presence in FDA databases does not by itself establish active commercial marketing. FDA records may continue to identify an approved product even after commercial discontinuation, depending on the regulatory status and the agency’s classification.

What patents protect Acanya?

Acanya’s protection relied on formulation and combination-product claims rather than composition-of-matter protection for a new chemical entity. Clindamycin and benzoyl peroxide were both established pharmaceutical ingredients before Acanya’s approval.

The relevant patent categories were:

• Fixed-dose clindamycin and benzoyl peroxide compositions.
• Stable topical gel formulations.
• Manufacturing and physical-compatibility characteristics.
• Potential method-of-use claims for treating acne.

The Orange Book is the controlling public source for determining which patents were listed against Acanya’s NDA, their listed expiration dates, and whether the listings remain active. Public company filings do not establish a reliable current patent-life calculation for Acanya by themselves.[5]

The commercial implication is clear: formulation patents can delay generic entry, but they generally provide narrower protection than a new chemical entity patent. A generic applicant can challenge listed patents, design around formulation limitations, or rely on patents that have expired.

When did Acanya lose exclusivity?

Acanya’s market exclusivity should be analyzed in separate categories:

Exclusivity type	Commercial significance
New-drug exclusivity	Limited post-approval period under the FDA approval framework
Patent exclusivity	Dependent on Orange Book-listed formulation or method patents
Trademark protection	Does not prevent sale of equivalent generic products
Formulation differentiation	Can support pricing only while enforceable and clinically relevant
Generic substitution	Main long-term erosion mechanism

The exact date of commercial loss of exclusivity cannot be inferred solely from the FDA approval date. Patent expiration, ANDA approvals, Paragraph IV litigation, settlements, and product-specific launch decisions determine actual generic entry.

Acanya’s practical exclusivity position is weaker than that of a product with an unexpired composition patent. Its protection was tied to a topical combination and formulation technology, while the underlying ingredients were old and widely available.

Were there Paragraph IV challenges or patent litigation involving Acanya?

Paragraph IV certifications are the principal mechanism by which an ANDA applicant challenges an Orange Book-listed patent. A generic applicant may assert that a listed patent is invalid, unenforceable, or not infringed.

The commercial record indicates that generic competition emerged in the clindamycin/benzoyl peroxide topical category. However, a complete product-specific litigation chronology requires confirmation from FDA Orange Book records, ANDA litigation dockets, and district court filings. Public corporate filings do not provide a complete, continuously updated Acanya litigation history.

The most relevant legal risks were:

• Invalidity challenges against formulation patents.
• Non-infringement arguments based on different excipients or manufacturing methods.
• Disputes over whether listed patents properly covered the approved product.
• Settlement agreements that could permit a defined generic launch date.
• Commercial launch before final resolution if the generic sponsor accepted litigation exposure.

No reliable public basis supports assigning a specific settlement date or generic first-launch date without product-level docket verification.

What generic products compete with Acanya?

Generic competition includes clindamycin phosphate and benzoyl peroxide topical gels that match or closely approximate Acanya’s active ingredients and strengths. Generic manufacturers in the broader topical dermatology market include companies such as Perrigo, Teva, Taro, Actavis or its successor businesses, and other FDA-approved ANDA sponsors, depending on the specific product and period.

Competition occurs on four levels:

Competitive layer	Examples
Direct generic substitutes	Clindamycin phosphate/benzoyl peroxide gels
Branded combinations	Duac and other branded or authorized-generic products
Ingredient alternatives	Generic benzoyl peroxide, clindamycin, and topical retinoids
Newer branded acne drugs	Topical retinoid, antibiotic, and hormonal products

A generic does not need to replicate every commercial attribute of the brand to pressure pricing. Pharmacy benefit managers may prefer lower-cost products, and physicians can prescribe by generic name.

How does Acanya compare with Duac?

Acanya and Duac are closely related products but are not identical.

Attribute	Acanya	Duac
Clindamycin strength	1.2% clindamycin phosphate	1.2% clindamycin phosphate
Benzoyl peroxide strength	2.5%	5%
Dosage form	Topical gel	Topical gel
Market position	Branded fixed-dose acne product	Branded fixed-dose acne product
Generic exposure	High	High
Differentiation	Lower benzoyl peroxide concentration and formulation	Higher benzoyl peroxide concentration and separate formulation history

The products compete clinically but may differ in tolerability, vehicle, formulation stability, and patient preference. Neither has the protection of a novel active ingredient. A physician may select between them based on acne severity, irritation risk, formulary status, or prior treatment response.

What is the revenue exposure for Bausch Health?

Acanya is unlikely to represent a material current revenue driver for Bausch Health. The company’s public reporting has historically emphasized larger or more strategic pharmaceutical and dermatology assets rather than individual mature topical products.

Revenue exposure is best characterized as:

• Historically meaningful within a specialty dermatology portfolio.
• Limited relative to Bausch Health’s consolidated revenue.
• Vulnerable to generic substitution.
• Unlikely to support material future growth.
• More relevant to portfolio cleanup, manufacturing economics, and residual intellectual property than to corporate valuation.

Bausch Health reported total revenue of approximately $9.2 billion in 2023, with results spread across pharmaceuticals, vision care, and other businesses. Acanya was not separately reported as a material revenue category in the company’s public annual reporting.[6]

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers for Acanya are moderate rather than severe. A generic sponsor must reproduce the relevant quality attributes of a semisolid topical product, including:

• Active-ingredient uniformity.
• Viscosity and spreadability.
• Particle size and suspension characteristics.
• Microbial limits.
• Stability over the labeled shelf life.
• Container-closure compatibility.
• In-vitro release or other comparative performance measures.

These requirements can delay approval or increase development cost, but they do not create the same barrier as sterile injectables, complex biologics, or advanced delivery systems.

The principal residual IP barrier is formulation-specific. If an unexpired patent covers a particular gel vehicle, stabilizer system, or manufacturing process, a generic sponsor may need to design around it. That barrier is narrower than a broad composition patent and generally weakens as more non-infringing formulations enter the market.

What generic launch scenarios exist for Acanya?

The principal scenarios are:

Scenario	Likely market effect
Multiple generic entrants	Rapid price erosion and near-complete brand substitution
Limited generic supply	Slower price decline but continued formulary pressure
Brand discontinuation	Generic products become the practical treatment substitutes
Authorized generic or licensed supply	Retains some manufacturer economics while reducing brand pricing
Formulary exclusion	Accelerates volume loss even if the brand remains technically available

The highest-probability long-term scenario is continued erosion of branded demand. A late-stage branded relaunch would require a strong commercial reason, such as a meaningful formulation improvement, new delivery technology, or a payer-supported niche. The existing active ingredients do not independently support a high-growth thesis.

What is Acanya’s patent strength and investment outlook?

Acanya’s patent estate is best characterized as moderate-to-weak from a long-term investment perspective.

Factor	Assessment
Active-ingredient novelty	Low
Formulation differentiation	Moderate
Manufacturing complexity	Moderate
Generic substitution risk	High
Biosimilar risk	None
Revenue visibility	Low
Growth potential	Low
Residual licensing value	Limited and formulation-dependent

The product can retain niche value if a specific formulation has clinical or tolerability advantages and if generic supply is constrained. That value is unlikely to create a durable, high-margin franchise without active enforcement, strong payer coverage, or a differentiated delivery system.

Key Takeaways

• Acanya is a clindamycin phosphate 1.2% and benzoyl peroxide 2.5% topical gel for acne.
• Medicis launched the product; Valeant acquired Medicis in 2012; Bausch Health later became the corporate successor.
• No reliable standalone Acanya revenue series is publicly disclosed.
• The product’s financial trajectory was shaped by generic substitution and mature-category pricing pressure.
• Acanya has no biosimilar risk because it is a small-molecule topical product.
• Its IP position depends on formulation and combination-product patents, not new-chemical-entity protection.
• Generic competition presents the principal commercial threat.
• Acanya is unlikely to be a material current revenue driver for Bausch Health.
• Manufacturing barriers are manageable and lower than those for biologics or complex injectables.
• The product has limited standalone growth or licensing value unless a differentiated formulation remains commercially protected.

FAQs

Is Acanya still available in the United States?

Acanya’s commercial availability is distinct from its FDA approval status. Public FDA records may identify the approved product even when branded distribution has ended or become limited. Generic clindamycin phosphate and benzoyl peroxide products provide the principal market alternatives.

Is Acanya the same as clindamycin and benzoyl peroxide gel?

Acanya contains clindamycin phosphate 1.2% and benzoyl peroxide 2.5%. A generic product with the same active ingredients and strength may be therapeutically substitutable, but its inactive ingredients, vehicle, container, and labeling can differ.

Does Acanya have a biologic or biosimilar competitor?

No. Acanya is not a biologic. Its competitive set consists of generic topical drugs, branded acne combinations, and alternative topical or oral acne therapies.

Can a company license Acanya’s formulation patents?

Potentially, but the value depends on the current status, ownership, enforceability, and remaining term of any formulation patents. A trademark or historical formulation claim alone would not justify a material licensing valuation.

What is the biggest investment risk associated with Acanya?

The primary risk is that generic products can replace the branded product at materially lower prices. Because the active ingredients are established and the formulation is a topical gel, the product has limited protection against payer-driven substitution.

References

1. U.S. Food and Drug Administration. (2008). Acanya (clindamycin phosphate and benzoyl peroxide) gel: Prescribing information.
2. Valeant Pharmaceuticals International, Inc. (2012). Annual report for the fiscal year ended December 31, 2012.
3. Valeant Pharmaceuticals International, Inc. (2015). Annual report for the fiscal year ended December 31, 2015.
4. Bausch Health Companies Inc. (2018). Annual report for the fiscal year ended December 31, 2018.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. Bausch Health Companies Inc. (2024). Annual report for the fiscal year ended December 31, 2023.